First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: Tarlatamab
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Atezolizumab
DRUG: Durvalumab

Sponsor

Amgen